Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR) γ agonists that are used to lower insulin resistance in Type 2 diabetic patients. Although TZDs exhibit beneficial effects on the vasculature, their effects on the heart are less clear and are the subject of current clinical debate. Thiazolidinediones have been reported to reduce adverse myocardial remodelling, a pathology in which cardiac myofibroblasts (CMF) are pivotal. The aim of the present study was to investigate whether TZDs modulate specific human CMF functions of importance to the myocardial remodelling process and to determine whether any of these effects were mediated via PPARγ activation. Immunoblotting of cultured human CMF homogenates revealed strong expression of PPARγ (approximately 50 kDa). Three different TZDs (ciglitazone, rosiglitazone and troglitazone) and the endogenous PPARγ ligand 15-deoxy-δ12,14-prostaglandin J2 (15d-PGJ2) inhibited CMF proliferation (cell number and expression of proliferating cell nuclear antigen) in a concentration-dependent manner (range 0.1-10 mol/L) with similar potencies. This antiproliferative effect of TZDs was not reversed by the PPARγ antagonists GW9662 or T0070907 (10-25 mol/L). None of the TZDs or 15d-PGJ2 affected cell migration or invasion (Boyden chamber assays without or with Matrigel barrier), matrix metalloproteinase-2 or -9 secretion (gelatin zymography) or the actin cytoskeleton (rhodamine/phalloidin fluorescent confocal microscopy). In conclusion, TZDs reduce human CMF proliferation via a PPARγ-independent mechanism. Although TZDs do not inhibit CMF invasion, their antiproliferative activity may contribute to the ability of this class of drugs to modulate adverse myocardial remodelling.
|Number of pages||9|
|Journal||Clinical and Experimental Pharmacology and Physiology|
|Publication status||Published - 1 May 2009|